BackTable / Urology / Podcast / Episode #245

Intravesical Therapies for Intermediate Risk Bladder Cancer

with Dr. Lindsey Herrel

With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.

This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved on June 12, 2025.

UroGen Pharma

Intravesical Therapies for Intermediate Risk Bladder Cancer with Dr. Lindsey Herrel on the BackTable Urology Podcast

Ep 245 Intravesical Therapies for Intermediate Risk Bladder Cancer with Dr. Lindsey Herrel

00:00 / 01:04

BackTable, LLC (Producer). (2030, July 1). Ep. 245 – Intravesical Therapies for Intermediate Risk Bladder Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Lindsey Herrel

Dr. Lindsey Herrel is a urologic oncologist practicing at the University of Michigan.

Dr. Ruchika Talwar

Dr. Ruchika Talwar is a urologic oncologist at Vanderbilt University Medical Center in Nashville, Tennessee.

Synopsis

The doctors break down the nuances of defining this risk category and the clinical gray zones that complicate treatment decisions. Dr. Herrell shares her patient-centered approach to surveillance and therapy, and introduces promising new agents, including Anktiva, UGN-102, and the gemcitabine-releasing TAR-200 "pretzel" device. The discussion also highlights how advances in molecular profiling are reshaping care strategies.

This episode underscores the urgent need for clearer guidelines and continued innovation to improve outcomes and quality of life for patients with this nuanced disease subtype.

Timestamps

00:00 - Introduction
02:03 - Defining Intermediate Risk Bladder Cancer
06:12 - Intravesical Therapy Options
08:47 - Quality of Life and Patient Counseling
10:18 - New Treatments on the Horizon
12:56 - Practical Tips for TURBT Recovery
17:03 - In-Office Procedure Management
21:38 - Managing Symptoms and Quality of Life
31:50 - A Note on Smoking Cessation
33:37 - Conclusion and Future Directions

Read Transcript

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

Genomic Classifiers in Bladder Cancer Management with Dr. Carissa Chu on the BackTable Urology Podcast

NMIBC Tumor Board: Upper Tract Challenges with Dr. Mark Tyson and Dr. Sarah Psutka on the BackTable Urology Podcast

NMIBC Tumor Board: Nuances in Management with Dr. Mark Tyson and Dr. Sarah Psutka on the BackTable Urology Podcast

Techniques & Challenges in Bladder Transplant Surgery with Dr. Nima Nassiri on the BackTable Urology Podcast

Enhancing Care Coordination in Bladder Cancer Treatments with Brynn Moore and Meredith Donahue on the BackTable Urology Podcast

Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Non-Muscle Invasive Bladder Cancer (NMIBC) Podcasts

Transurethral Resection of Bladder Tumor (TURBT) Podcasts

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.